Literature DB >> 30980814

High-throughput screening identifies compounds that protect RPE cells from physiological stressors present in AMD.

Hui Cai1, Jie Gong1, Laura Abriola2, Denton Hoyer2, Scott Noggle3, Daniel Paull3, Lucian V Del Priore1, Mark A Fields4.   

Abstract

Dysfunction and eventual loss of retinal pigment epithelial (RPE) cells is a hallmark of atrophic age-related macular degeneration (AMD), and linked to oxidative and nitrosative damage. Herein, we use a high-throughput screen (HTS) to identify compounds that protect human RPE cells from oxidative stress-induced cell death and elucidate the possible mechanism of action. HTS was used to identify compounds that protect RPE cells from oxidative damage. We tested the identified compound(s) in models of RPE stress, including tert-butyl hydroperoxide (TBHP) exposure, ultraviolet-B (UV-B)-mediated light damage and nitrosative stress to the basement membrane using ARPE-19 cells, primary human RPE cells and induced-pluripotent stem cell (iPSC)-derived RPE cells from patients with AMD. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to detect gene expression of oxidative stress- and apoptosis-related genes and mitochondrial function was measured using a Seahorse XF96 analyzer to elucidate possible mechanisms of action. Five thousand and sixty-five compounds were screened, and of these, 12 compounds were active based on their ability to improve cell viability after exposure to TBHP. After chemical structure review, we identified ciclopirox olamine as a potent inhibitor of oxidative damage to RPE cells. Ciclopirox olamine increased cell viability in ARPE-19 cells treated with TBHP, UV-B light or on nitrite-modified extracellular matrix (ECM) by 1.68-fold, 1.54-fold and 4.3-fold, respectively (p < 0.01). Treatment with TBHP altered expression of genes related to oxidative stress and apoptosis, which was reversed by pretreatment with ciclopirox olamine. Ciclopirox olamine improved mitochondrial function in TBHP-exposed ARPE-19 cells and iPSC-derived RPE cells. Ciclopirox olamine protected primary human RPE cells and iPSC-derived RPE cells from the oxidative stress or damaged basement membrane. HTS of bioactive Food and Drug Administration (FDA)-approved libraries and follow-up studies can be used to identify small molecules (including ciclopirox olamine) that protect RPE cells exposed to various stressors associated with disease progression of AMD. This strategy can be used to identify potential compounds for treatment and prevention of AMD.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Age-related macular degeneration; Ciclopirox olamine; Induced pluripotent stem cells; Oxidative stress; Retinal pigment epithelial cells

Mesh:

Substances:

Year:  2019        PMID: 30980814     DOI: 10.1016/j.exer.2019.04.009

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  4 in total

1.  Automating Human Induced Pluripotent Stem Cell Culture and Differentiation of iPSC-Derived Retinal Pigment Epithelium for Personalized Drug Testing.

Authors:  Vincent Truong; Kevin Viken; Zhaohui Geng; Samantha Barkan; Blake Johnson; Mara C Ebeling; Sandra R Montezuma; Deborah A Ferrington; James R Dutton
Journal:  SLAS Technol       Date:  2020-12-09       Impact factor: 2.813

2.  Crocetin Prevents RPE Cells from Oxidative Stress through Protection of Cellular Metabolic Function and Activation of ERK1/2.

Authors:  Padideh Karimi; Ali Gheisari; Sylvia J Gasparini; Hossein Baharvand; Faezeh Shekari; Leila Satarian; Marius Ader
Journal:  Int J Mol Sci       Date:  2020-04-22       Impact factor: 5.923

3.  A Human Retinal Pigment Epithelium-Based Screening Platform Reveals Inducers of Photoreceptor Outer Segments Phagocytosis.

Authors:  Sven Schreiter; Katerina Vafia; Rico Barsacchi; Stephen H Tsang; Marc Bickle; Marius Ader; Mike O Karl; Elly M Tanaka; Seba Almedawar
Journal:  Stem Cell Reports       Date:  2020-11-25       Impact factor: 7.765

4.  Testing Mitochondrial-Targeted Drugs in iPSC-RPE from Patients with Age-Related Macular Degeneration.

Authors:  Mara C Ebeling; Zhaohui Geng; Madilyn R Stahl; Rebecca J Kapphahn; Heidi Roehrich; Sandra R Montezuma; Deborah A Ferrington; James R Dutton
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.